Lab Rats series: A Pune biotech startup’s new approach to vitiligo cure
Executive Brief • Key Highlights
Fast factual intelligence distilled for busy investors, executives, and answer bots:
- ✓Pune biotech startup Ahammune has moved its vitiligo drug candidate, AB1001, into phase 2 clinical trials.
- ✓Chief executive Parul Ganju said, “We identified a pathway that leads to the trigger of this autoimmunity in the skin.” The team raised $8-9 million to develop this new treatment over ten years.
Story at a Glance
- Category
- BUSINESS
- Reported By
- Livemint
- Reading Speed
- 5 Minute(s)
- Market Focus
- India Economy
For chief executive Parul Ganju, an effective treatment must do more than halt the disease. It should stop the patches from spreading, restore pigmentation and ensure that the colour does not fade again.
After a decade of research, Ahammune has advanced its lead candidate, AB1001, to phase 2 clinical trials, with a team of just 10 and $8-9 million raised through grants and equity funding.
“That’s what has helped us in the last ten years to take the molecule into phase 2, at a fraction of the cost that any company outside India would spend,” Ganju said.
In drug development, phase 1 trials are focused primarily on establishing safety, tolerability and dose range in healthy volunteers, before they can progress to phase 2, tested in a larger group of patients to see how it works while still remaining safe.
Unlock the Full Story with ArthNow Premium
To continue reading this complete financial story and in-depth market context, upgrade to ArthNow Premium. Enjoy unlimited access across Web and Mobile.
Livemint
Read the full, original unfiltered story directly on the publisher's portal.